# 1 Mendelian randomization confirms the role of Y-chromosome loss in Alzheimer's

# 2 Disease etiopathogenesis in males

3	Pablo García-González MSc <sup>1,2</sup> *, Itziar de Rojas MSc <sup>1,2</sup> , Sonia Moreno-Grau PhD <sup>3,1</sup> ,
4	Laura Montrreal <sup>1</sup> , Raquel Puerta MSc <sup>1</sup> , Emilio Alarcón-Martín MsC <sup>1</sup> , Inés Quintela
5	PhD <sup>4</sup> , Adela Orellana PhD <sup>1</sup> , Victor Andrade MSc <sup>5,6</sup> , Pamela Martino Adami PhD <sup>5</sup> ,
6	Stefanie Heilmann-Heimbach PhD <sup>7</sup> , Pilar Gomez-Garre PhD <sup>8,2</sup> , María Teresa Periñán
7	MsC <sup>8,2</sup> , Ignacio Alvarez MsC <sup>9,10</sup> , Monica Diez-Fairen PhD <sup>9,10</sup> , Raul Nuñez Llaves
8	MsC <sup>1</sup> , Claudia Olivé Roig MSc <sup>1</sup> , Guillermo Garcia-Ribas MD, PhD <sup>11</sup> , Manuel
9	Menéndez-González MD, PhD <sup>12,13,14</sup> , Carmen Martínez MD, PhD <sup>15,13</sup> , Miquel Aguilar
10	MD <sup>9,10</sup> , Mariateresa Buongiorno MD, PhD <sup>9,10</sup> , Emilio Franco-Macías MD, PhD <sup>16</sup> ,
11	Maria Eugenia Saez PhD <sup>17</sup> , Amanda Cano PhD <sup>1,2</sup> , Maria Bullido PhD <sup>18,2,19</sup> , Luis Real
12	PhD <sup>20,21</sup> , Eloy Rodríguez-Rodríguez MD, PhD <sup>22,2</sup> , Jose Royo PhD <sup>21</sup> , Victoria Álvarez
13	PhD <sup>23,13</sup> , Pau Pastor MD, PhD <sup>9,10</sup> , Gerard Piñol-Ripoll PhD <sup>24,25</sup> , Pablo Mir MD,
14	PhD <sup>8,2,26</sup> , Miguel Calero Lara PhD <sup>2,27</sup> , Miguel Medina Padilla PhD <sup>2,28</sup> , Pascual Sánchez-
15	Juan MD, PhD <sup>28,22,2</sup> , Angel Carracedo PhD <sup>4,29</sup> , Sergi Valero PhD <sup>1,2</sup> , Isabel Hernandez
16	MD, PhD <sup>1,2</sup> , Lluis Tàrraga <sup>1,2</sup> , Alfredo Ramirez MD, PhD <sup>5,6,30,31,32</sup> , Mercé Boada MD,
17	PhD <sup>1,2</sup> , Agustín Ruiz MD, PhD <sup>1,2</sup>
18	CORRESPONDING AUTHOR: Pablo García González (pgarcia@fundacioace.org)
19	TLF: +34 649 737 121 ADRESS: Marques de Sentmenat 57, Barcelona, Spain 08029.
20	<sup>1</sup> Research Center and Memory Clinic, Ace Alzheimer Center Barcelona, Universidad
21	Internacional de Catalunya, Spain
22	<sup>2</sup> Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto
23	de Salud Carlos III, Madrid, Spain
	2

<sup>3</sup>Galatea Bio Inc., Hialeah, FL, USA

- <sup>4</sup>Grupo de Medicina Xenómica, Centro Nacional de Genotipado (CEGEN-PRB3-
- 26 ISCIII). Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- <sup>27</sup> <sup>5</sup>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and
- 28 Psychotherapy, University of Cologne, Medical Faculty, 50937 Cologne, Germany
- <sup>6</sup>Department of Neurodegenerative diseases and Geriatric Psychiatry, University Clinic
- 30 Bonn, 53127 Bonn, Germany
- 31 <sup>/</sup>Institute of Human Genetics, University of Bonn, School of Medicine & University
- 32 Hospital Bonn, 53127 Bonn, Germany
- <sup>8</sup>Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología,
- 34 Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del
- 35 Rocío/CSIC/Universidad de Sevilla, Seville, Spain
- <sup>9</sup>Fundació Docència i Recerca MútuaTerrassa, Terrassa, Barcelona, Spain
- <sup>10</sup>Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de
- 38 Terrassa, Terrassa, Barcelona, Spain
- <sup>11</sup>Hospital Universitario Ramon y Cajal, IRYCIS, Madrid
- 40 <sup>12</sup>Servicio de Neurología, Hospital Universitario Central de Asturias, Oviedo, Spain
- 41 <sup>13</sup>Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
- 42 <sup>14</sup>Departamento de Medicina, Universidad de Oviedo, Oviedo, Spain
- 43 <sup>15</sup>Servicio de Neurología, Hospital Universitario de Cabueñes, Gijón, Spain
- <sup>16</sup>Unidad de Demencias, Servicio de Neurología y Neurofisiología. Instituto de
- 45 Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del
- 46 Rocío/CSIC/Universidad de Sevilla, Seville, Spain
- 47 <sup>17</sup>CAEBI, Centro Andaluz de Estudios Bioinformáticos, Sevilla, Spain
- 48 <sup>18</sup>Centro de Biología Molecular Severo Ochoa, UAM-CSIC, Madrid, Spain
- 49 <sup>19</sup>Instituto de Investigacion Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain

- <sup>20</sup>Unidad Clínica de Enfermedades Infecciosas y Microbiología. Hospital Universitario
- 51 de Valme, Sevilla, Spain
- 52 <sup>21</sup>Departamento de Especialidades Quirúrgicas, Bioquímica e Inmunología. Facultad de
- 53 Medicina. Universidad de Málaga. Málaga, Spain
- <sup>22</sup>Neurology Service, Marqués de Valdecilla University Hospital (University of
- 55 Cantabria and IDIVAL), Santander, Spain
- <sup>23</sup>Laboratorio de Genética, Hospital Universitario Central de Asturias, Oviedo, Spain
- <sup>57</sup> <sup>24</sup>Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain
- <sup>25</sup>Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain
- <sup>26</sup>Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Seville,
- 60 Spain
- 61 <sup>27</sup>Instituto de Salud Carlos III, Majadahonda, Spain
- <sup>28</sup>Queen Sofia Foundation Alzheimer Center, CIEN Foundation, Madrid, Spain
- <sup>29</sup>Fundación Pública Galega de Medicina Xenómica- CIBERER-IDIS, Santiago de
- 64 Compostela, Spain
- <sup>30</sup>German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany
- <sup>31</sup>Department of Psychiatry and Glenn Biggs Institute for Alzheimer's and
- 67 Neurodegenerative Diseases, San Antonio, TX, USA
- <sup>32</sup>Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases
- 69 (CECAD), University of Cologne, Cologne, Germany
- 70

# 71 **ABSTRACT:**

Mosaic loss of chromosome Y (mLOY) is a common ageing-related somatic event occurring exclusively in men and has been previously associated with Alzheimer's disease (AD). However, mLOY estimation from genotype microarray data only reflects the mLOY degree of subjects at the moment of DNA sampling. Therefore, mLOY

76 phenotype associations with AD can be severely age-confounded in the context of genome-wide association studies. Here, we applied Mendelian randomization to 77 construct an age-independent polygenic risk score of mLOY (mloy-PRS) using 114 78 autosomal variants. The mloy-PRS instrument was associated with an 80% increase in 79 mLOY risk per SD unit ( $p=4.22\cdot10^{-20}$ ) and was orthogonal with age. We found that a 80 higher genetic risk for mLOY was associated with faster progression to AD in males 81 82 with mild cognitive impairment (HR=1.23; p=0.01). Importantly, mloy-PRS had no 83 effect on AD conversion or risk in the female group. The male-specificity of the 84 observed effects suggests that these associations of mLOY with AD are caused by the 85 inherent loss of the Y chromosome, and not by the increased genomic instability underlying mLOY risk. Additionally, we found that blood mLOY phenotype was 86 associated with increased CSF levels of total tau and phosphorylated tau181 in subjects 87 88 with mild cognitive impairment and dementia. Our results strongly suggest that mLOY is involved in AD pathogenesis. Furthermore, we encourage researchers to use this 89 90 mloy-PRS instrument to find unbiased associations between mLOY and ageing-related 91 diseases.

92

## 93 <u>INTRODUCTION</u>

94

Alzheimer's disease (AD) is the leading cause of dementia worldwide, accounting for 95 96 60-80% of total cases [1]. While Mendelian inheritance is suspected to cause early 97 onset AD (<65 years) [2], late onset AD (LOAD, >65 years) is a complex, multifactorial 98 disease influenced by both genetic factors and life exposures. The genetic contribution to LOAD is estimated to be 60-80% [3], being APOE the most prominent locus 99 100 discovered to date [4]. However, demographic features also play a predominant role in 101 AD. Notably, age is considered the most important risk factor for LOAD [5]. On the other hand, women represent nearly two thirds of the global population with AD [1] and 102 103 show higher rates of cognitive decline [6, 7] than men. However, whether sex should be considered a risk factor for AD or instead a source of disease heterogeneity is a matter 104 of intense debate [8]. Recent reviews highlighted the importance of reporting results for 105 106 sex interactions and sex-stratified AD data instead of the more widely used approach of adjusting data by sex [9]. These approaches may help elucidate differences in sex-107

specific AD risk profiles, which will be of great value in the incoming age of precisionmedicine.

110 The male-specific region of chromosome Y is one of the most unexplored regions of the human genome and has long been considered a genetic wasteland. Mosaic loss of 111 chromosome Y (mLOY) in blood cells is the most common known form of somatic 112 mosaicism in humans [10–12]. Genetic factors together with age, smoking and other 113 environmental stressors are well known risk factors for mLOY [13]. Genetic variants 114 115 associated with mLOY risk are mainly related to mitotic processes, cell cycle regulation, DNA damage sensing and response, and apoptotic processes [14]. mLOY 116 was initially considered a phenotypically innocuous, age-related trait [15–18]. However, 117 there is increasing evidence that mLOY in blood cells has a direct effect in the 118 119 etiopathogenesis of several diseases affecting different tissues. Specifically, blood cell 120 mLOY has been associated with susceptibility to multiple ageing-related diseases, i.e., AD [19], non-hematological cancer [10, 20], cardiovascular diseases [21, 22] and all-121 cause mortality risk [10]. The main proposed mechanism to explain blood mLOY 122 123 pathogenesis is by impairment of immune functions caused by the loss of the Y chromosome in leukocytes [23-25]. However, it has been described that autosomal 124 125 genetic predisposition for mLOY is associated with breast cancer in women, indicating 126 that the underlying genomic instability can also explain the associations between mLOY 127 and disease risk [14].

128 Here, we aimed to study mLOY's impact on AD risk in the GR@ACE and Dementia 129 Genetics Spanish Consortium (DEGESCO) cohorts [26, 27]. First, we checked for blood mLOY associations with AD in both a case-control setting and in the 130 phenoconversion process from mild cognitive impairment (MCI) to all-cause dementia 131 and AD. Subsequently, to remove age confounding effects, we generated an autosomal, 132 age-independent polygenic risk score (PRS) of mLOY and analysed its effect on AD 133 status and progression in both sexes. Finally, we analysed mLOY's impact in different 134 AD-related biomarkers in CSF. 135

136

137

138

#### 139 <u>METHODS</u>

140

#### 141 - The GR@ACE-DEGESCO cohort

142 The GR@ACE-DEGESCO cohort comprises AD patients and controls from the 143 Spanish population. AD patients were collected from ACE Alzheimer Center Barcelona and 12 other cohorts included in the Dementia Genetics Spanish Consortium 144 (DEGESCO) (Supplementary Table 1). Control individuals were provided by ACE 145 Alzheimer Center (Barcelona, Spain), Valme University Hospital, the Spanish National 146 DNA Bank Carlos III (Salamanca, Spain) and other DEGESCO members. DNA 147 148 extracted from peripheral blood or saliva (Supplementary Table 1) was genotyped in the Spanish National Center for Genotyping (CeGen, Santiago de Compostela, Spain), 149 150 using the Axiom 815K Spanish Biobank Array (Thermo Fisher), as previously described [26, 27]. 151

### 152 - The ACE MCI-EADB cohort.

The EADB cohort is a prospective cohort conformed by MCI individuals recruited 153 154 between 2006 and 2013 at ACE Alzheimer Center Barcelona. Briefly, individuals with a Clinical Dementia Rating Scale (CDR) of 0.5 and older than 60 years were selected 155 156 and underwent at least one follow-up, consisting of neurological, neuropsychological and social work evaluations. Detailed definition of the ascertainment of this cohort has 157 been described [28, 29]. DNA genotyping was performed as described elsewhere [30]. 158 159 Briefly, DNA extracted from peripheral blood was genotyped with the Illumina 160 Infinium Global Screening Array (GSA, GSAsharedCUSTOM\_24+v1.0) in LIFE & BRAIN CENTER, (EADB node, Bonn, Germany) and SNP genotype calls were 161 162 obtained from raw probe intensity data in the same center.

## 163 - Criteria for AD diagnosis, case-control setup

AD diagnoses were established in all cases by a multidisciplinary working group conformed by neurologists, neuropsychiatrists and social workers, following DSM-IV criteria for dementia and the National Institute on Aging and Alzheimer's Association's (NIA-AA) 2011 guidelines for AD definition. In the present study, individuals were

168 labeled as AD when possible or probable AD was endorsed by neurologists at any point

169 of their clinical history. Written informed consent was obtained from all participants.

170 The Ethics and Scientific Committees have approved this research protocol (Acta

171 25/2016, Ethics Committee. H., Clinic I Provincial, Barcelona, Spain).

#### 172 Assessment of MCI to dementia/AD conversion

MCI to dementia conversion was determined by integrating CDR, Global Deterioration 173 174 Scale (GDS), and diagnostic assessments at ACE Alzheimer Center Barcelona, assigned 175 at a consensus conference including neurologists, neuropsychologists and social workers [31]. Conversion to dementia was defined as the first clinical evaluation 176 reporting a diagnosis of AD [32, 33], vascular dementia [34], mixed dementia (AD with 177 cerebrovascular disease), frontotemporal dementia [35, 36] or dementia with Lewy 178 bodies [37], combined with a CDR change from 0.5 to >=1, and GDS >=4. AD 179 180 converters were defined as the fraction of converters to dementia that were diagnosed with AD. Baseline criteria varied depending on whether the exposure was mLOY 181 182 phenotype or it's associated PRS: In the first case, baseline was defined as the moment of blood sampling used afterwards for germline DNA extraction, genome-wide 183 184 genotyping and mLOY estimation. We selected only those individuals who met 185 Petersen's criteria [38, 39], for amnestic and non-amnestic MCI, at the closest clinical 186 evaluation to DNA sampling. Because genotypes used for PRS estimates are invariable, baseline was defined as the patient's first clinical record meeting Petersen's criteria for 187 188 PRS analysis. Follow-up time was defined as the time window between baseline and: (a) the date of conversion to dementia (converters) and (b) the date of last clinical 189 190 evaluation (non-converters). In order to have a prospective cohort, disease progression models only included individuals who were either originally selected as controls/MCIs 191 192 in the GR@ACE-DEGESCO case-control cohort, or present in the MCI cohort (ACE 193 MCI-EADB).

## 194 LOY determination

PennCNV [40-42] was used to process CEL files, following the recommended
workflow for Affymetrix arrays [43] to obtain Log R Ratio (LRR) and B allele
frequency (BAF) values for each array probe in our dataset. Determination of mLOY
was performed using MADloy package for R [44]. Briefly, this method estimates

mLOY by normalizing the median LRR of probes found at the male specific region of 199 chromosome Y (mLRR-Y), against the 5% trimmed mean LRR of autosomal 200 201 chromosomes. Thus, only probes located between pseudoautosomal regions 1 (PAR1) 202 and 2 (PAR2) in chromosome Y, excluding the X transposed region, (chrY:6611498-203 24510581; hg19/GRCh37) are used to compute mLRR-Y. To call mLOY status, we 204 used the mLRR-Y<sub>thres</sub> method of the MADloy package. Briefly, a threshold is 205 determined by extrapolating the 99% confidence interval of the positive side of the 206 cohort mLRR-Y distribution [10]. Then, samples with mLRR-Y values below the 207 empirically calculated threshold are assigned mLOY status (or calls). To overcome 208 computational power limitations, mLOY calls were obtained in two randomized 209 batches. B-deviation (Bdev), defined as the mean deviation from the expected BAF (0.5) for heterozygous SNPs, located in PAR1 regions (PAR1-Bdev) was used as a 210 211 complementary indicator of mLOY (Supplementary Figure 1).

#### 212 Sample processing and QC

213 LRR and BAF values for all biallelic markers were obtained from 20 068 CEL files (call rate >0.97 per sample and >0.985 per plate). Then, reported male samples were 214 215 retrieved, and samples with mean LRR-X and LRR-Y corresponding to female (XX) or 216 sexual chromosome aneuploidies were discarded. Additionally, samples with high 217 heterozygosity rate, high chromosome X heterozygosity and population outliers were removed from our dataset. Samples with LRR SD > 0.46, a standard QC parameter for 218 219 Affymetrix LRR data, were removed. GENESIS R package [46] was used to examine 220 relatedness within our dataset. Second degree relatives were detected by using a kinship 221 threshold of 0.046875 and were filtered out of the dataset. Finally, outliers in the 222 mLRR-y and b-deviation distribution were removed. Specific QC procedures and 223 sample filtering steps for each analysis are summarized in Supplementary Figure 2.

#### 224 mLOY autosomal Polygenic Risk Score

Processing, QC and imputation of the genome-wide SNP data were performed as described elsewhere [27, 30]. An mLOY autosomal polygenic risk score (mloy-PRS) was calculated based on independent genome-wide significant variants previously described [14]. Out of the 156 reported SNPs, we excluded those unavailable in our dataset, considered rare variants (MAF<0.01), with low imputation quality ( $R^2$ <0.3), or

located within the sexual chromosomes, leaving us with a final number of 114
autosomal SNPs (Supplementary Table 2). mloy-PRS was calculated for all individuals
in the GR@ACE-DEGESCO and ACE MCI-EADB cohorts by adding the dosage of
risk alleles weighted by their reported effect sizes (beta coefficients). To ease
interpretation of results, mloy-PRS units were standardized (SD=1).

#### 235 Core AD biomarkers & targeted proteomics

Levels of Abeta-42, tau phosphorylated at position 181 (p-tau) and total tau were
measured the same day in cerebrospinal fluid (CSF) samples obtained via lumbar
punctures using commercially available ELISA immunoassays (INNOTEST® βAMYLOID (1-42), INNOTEST® hTAU, and INNOTEST® PHOSPHO-TAU(181P)
(Fujirebio, Spain).

CSF and paired plasma samples collected the same day, as described elsewhere [47, 48],
underwent targeted proteomics using ProSeek® multiplex immunoassay by Olink
Proteomics (Uppsala, Sweden). Protein concentration was measured for 184 proteins
included in the commercially available ProSeek® Multiplex panels (Inflammation &
Neurology) in both fluids. Quality control details and further description of this data are
provided elsewhere [49].

## 247 Statistical Analysis

Data processing and analysis was performed with R Software [50]. To harmonize effect 248 249 directions, the mLRR-Y variable was multiplied by -1 due to lower values of mLRR-Y 250 representing a higher degree of mLOY. Logistic regressions adjusted by age, APOE 251 genotype and population structure were fitted for case-control analysis. Survival R 252 package [51] was used to fit Cox proportional-hazards models to assess MCI conversion to all-cause dementia or AD. Due to the age-dependent nature of mLOY [11, 52], only 253 individuals with available age at DNA sampling information were used for analyses 254 255 involving mLOY or mLRR-Y. To correct for population structure, only the principal 256 components (PCs) that were associated with the dependent variable were included in the 257 models. Population structure was not corrected in the Cox models as PCs showed no effect on disease progression (Supplementary Table 3, Supplementary Figure 3), likely 258 because all MCI samples came from the same center (ACE Alzheimer Center 259

Barcelona). APOE genotypes were modelled as a continuous variable ranging from -2 to 260 261 2, where each APOE- $\varepsilon$ 2 allele contributed with -1 and each APOE- $\varepsilon$ 4 allele added +1, as previously described [29]. In order to control ascertainment and genotyping bias 262 263 between MCI cohorts (GR@ACE-DEGESCO & ACE MCI-EADB), a dichotomic variable was introduced in models testing association of mloy-PRS with disease 264 265 progression. For analysis of Olink proteomic data, linear regressions were adjusted by 266 age, the time window between DNA sampling and lumbar puncture, and APOE 267 genotype. Due to the high correlation between many CSF proteins, total tau and p-tau 268 levels (Supplementary Figure 4), we also included models adjusted by total tau levels. Fixed-effect inverse variance weighted meta-analysis was performed with the rma.uni 269 270 function included in the metafor R package [53].

271

## 272 <u>RESULTS</u>

273

We computed mean LRR-Y and LRR-X values for 7 954 clinically reported male 274 275 samples and plotted these values, generating clusters that allowed us to check the sexual 276 chromosome dosages of these individuals (Supplementary Figure 5). We detected one 277 individual with a gain of chromosome Y (GOY, XYY) compatible with a supermale 278 syndrome and three individuals with Klineffelter syndrome (XXY). Women (XX), GOY, Klineffelter individuals, and outliers were discarded prior to mLOY computation. 279 For the 7 843 remaining XY individuals, we removed second-degree or lower relatives, 280 281 and samples with low genotype call rate ( $\leq 0.97$ ) or excess heterocigosity (>3SD over 282 cohort mean heterocigosity). We ran principal component analysis to identify the 283 population structure and removed 72 individuals from non-European population (>6SD 284 from 1000 Genomes European population mean). Subjects with detectable autosomal 285 chromosomopathies, i.e., Down's Syndrome, were also excluded. After applying these 286 exclusion criteria, we split the remaining 6 955 male samples in two randomized 287 batches and performed mLRR-Y computation and mLOY calling. We did not detect batch effect due to cohort splitting (Supplementary Figure 6). We excluded 12 288 289 additional samples with LRR SD > 0.46. Finally, we plotted mLRR-Y and PAR1-290 Bdev values in order to identify and remove individuals with detectable anomalies in 291 chromosome Y (i.e. partial loss of chromosome Y) or loss of heterocigosity in the

292 PAR1 region (Supplementary Figure 5). QC and filtering steps for analysis of mLOY

phenotypes and mloy-PRS of our data are summarized in Supplementary Figure 2.

294

295 To have a first glimpse at our data, mLRR-Y values of all AD cases and controls were 296 plotted with respect to age (Figure 1). The first thing that became apparent was that our 297 population significantly AD control is younger than the population. 298 Additionally, mLOY occurrence before 65 years was a very rare event in our 299 cohort, indicating that our control population below this age threshold may not be 300 representative for assessing mLOY's effect on AD. Moreover, our control population 301 mostly lacked individuals older than 85 years. Consequently, we decided to stablish a 302 65–85 age window for analyzing mLOY's effect on AD. This matches the usual age at onset range for preclinical, prodromal, and mild dementia stages for LOAD in our 303 304 population [31] and helped reduce the age gap between our case and control groups (Supplementary Table 4). Concordant with previous reports, we observed a clear age-305 306 related increase of mLOY events in the older individuals (Figure 1). Age was associated 307 with mLOY occurrence in males aged 65-85, with an estimated 1% increase in the chance of developing LOY every year ( $p=3.50\cdot10^{-11}$ ). 308

309

Then, we assessed if continuous mLRR-Y values were differentially distributed amongst cases and controls. Both unadjusted Kolmogorov-Smirnoff test (D=0.18124; p  $< 2.2 \cdot 10^{-16}$ ) and ANCOVA adjusted by age at DNA sampling and *APOE* (F=68.0; p=2.54 \cdot 10^{-16}, Supplementary Table 5) yielded highly significant results in models including all available males in our cohort.

Next, we fitted logistic regressions for AD status using mLOY calls and mLRR-Y, defining 3 experimental setups: a) all men with available age at DNA sampling, b) 65– 85-year-old men and c) dividing the data in age groups (65–70, 70–75, 75–80 & 80–85 years old). Logistic regressions were adjusted by age at blood sampling, *APOE* genotype and relevant PCs (Supplementary Table 6).

We found that the continuous mLRR-Y variable was associated with AD in the group including all men (N=2 697; OR=2.74; p=0.01), indicating that AD cases had an increased degree of LOY mosaicism compared to controls. We also observed increased mLOY levels in AD males in the 65–85 (N=1 944; OR=2.19; p=0.09) and stratified age groups (Table 1) with respect to controls, but these differences were not statistically significant. Importantly, we noticed that the significant effect observed in the model

including all available males could be, at least partially, driven by the dramatic age differences between AD cases and controls in our cohort (Figure 1, Supplementary Table 4), even after adjusting our data by age. mLOY calls were not significantly associated to AD in the group including all men (N=2 697; OR=1.14; p=0.35), the 65– 85-year-old group (N=1 944; OR=1.04; p=0.81), nor in the age-stratified groups (Table 1).

332

333 In order to check for an effect of mLOY in risk of conversion to all-cause dementia and 334 AD, we fitted Cox proportional-hazards models adjusted by age at sampling and APOE genotype in our prospective cohort of MCI males (N=400). The continuous mLRR-Y 335 336 variable had a non-significant risk effect in MCI conversion to all-cause dementia (HR=1.93; p=0.10). The effect size increased when we calculated the model exclusively 337 338 using conversion to AD but did not reach statistical significance (HR=2.05; p=0.19). mLOY calls also showed similar but smaller non-significant positive effects for 339 340 conversion to dementia (HR=1.17; p=0.40) and AD (HR=1.38; p=0.20, Figure 2). Cox 341 model results are summarized in Table 2.

342

343 Because the impact of age on mLOY and AD might obscure genuine associations 344 between both phenotypes (mLOY and AD), we decided to construct a mLOY Polygenic Risk Score (mloy-PRS) to evaluate the impact of the genetic variance 345 associated with mLOY phenotype in AD risk. Our rationale was to implement a 346 Mendelian randomization strategy reasoning that, if blood cell mLOY is genuinely 347 348 associated with AD, the genetic factors linked to blood mLOY risk should be also 349 associated with AD and its related endophenotypes. To this end, mloy-PRS was 350 generated based on a list of autosomal genome-wide significant SNPs associated with 351 the mLOY phenotype identified in a recent genome-wide association study (Supplementary Table 2) [14]. 352

For benchmarking purposes of the constructed PRS, we initially validated the effect of 353 354 mloy-PRS in the mLOY cell phenotype in our cohort (65–85 years old). To this end, we fitted a logistic regression for mLOY calls with PRS, age at DNA sampling and APOE 355 genotype as predictors. The PRS (OR=1.80; p= $4.22 \cdot 10^{-20}$ ) and age at sampling 356  $(OR=1.08; p=5.07\cdot10^{-11})$ , but not APOE (OR=0.88; p=0.15), were significantly 357 associated with mLOY in our population (Supplementary Table 7). Importantly, the 358 359 PRS was orthogonal with age and evenly distributed across the age

spectrum (Supplementary Figure 7). Our results reassure the validity of mloy-PRS as a mendelian randomization instrument for investigating the causal role of mLOY in AD and its endophenotypes, and independently confirm the combined risk effect of previously reported loci in the mLOY phenotype [14].

364

In the case-control setup, we checked the effect of mloy-PRS on AD risk by fitting 365 366 logistic regressions adjusted by APOE, age and relevant PCs (Supplementary Table 367 8). Interestingly, the effect of mloy-PRS on AD could be measured in the female 368 samples as well. Therefore, 3 analysis groups were stablished: all (males + females) and stratified by sex. No association between mloy-PRS and AD was found in the group 369 370 including both sexes (Table 3). However, after sex stratification, we found a weak nonsignificant positive effect of mloy-PRS with respect to AD in the male subgroup (N=2 371 372 471; OR=1.07; p=0.12), while the effect was mostly neutral in the female subset (N=4 978; OR=1.00; p=0.93). Next, we assessed the effect of mloy-PRS in disease 373 374 progression. We adjusted Cox models by age, APOE genotype and cohort 375 ascertainment. We found a male-specific positive effect of mloy-PRS in the disease progression models (N=682) (Table 3, Supplementary Figure 8), with a suggestive 376 377 signal for MCI to dementia progression (HR=1.11; p=0.08) and a statistically significant risk effect for MCI to AD progression (HR=1.23; p=0.01). Of note, no association 378 between mloy-PRS and conversion to all-cause dementia (HR=0.99, p=0.81) or AD 379 380 (HR=0.99; p=0.85) was found in the female group  $(N=1\ 0.82)$ .

381

382 Following these results. we proceeded to examine the existence 383 of associations between mLRR-Y, the continuous mLOY variable, and the levels of core AD biomarkers in CSF (Abeta-42, p-tau and total tau). Only individuals aged 384 385 65–85 at the moment of lumbar puncture (LP) were kept, and those with a gap higher than 5 years between DNA sampling and the LP were excluded from the analysis 386 (N=214). Linear regressions were adjusted by APOE genotype, age at LP, and 387 388 time window between blood sampling and LP. To account for the effect of syndromic status on the levels of Abeta-42, p-tau and total tau, we calculated the effect in two 389 groups (MCI N=148; dementia N=66) and then performed inverse-variance weighted 390 391 fixed effect meta-analysis of the effect of mLRR-Y. We found that both p-tau ( $\beta$ =41.92; p=0.01) and total tau ( $\beta$ =396.69; p=0.004) levels were increased in individuals with a 392 393 higher degree of mLOY (Figure 3).

394

Afterwards, we checked for mLRR-Y associations with proteomics data obtained with 395 396 the Olink ProSeek® multiplex immunoassay for paired plasma and CSF samples in 135 397 MCI males. Because mLOY is known to affect the immune system [10, 24, 54], and inflammation is involved in many processes related to AD pathogenesis [55], we 398 399 analysed Olink Neurology and Inflammation panels. We detected inflation in our 400 models ( $\lambda$ =1.86), with most proteins showing increased levels in the CSF of individuals 401 with a higher degree of blood mLOY (Figure 3). A similar pattern was observed when 402 we analysed the effect of APOE genotype and total tau levels, with a big fraction of the 403 proteins showing increased CSF levels in individuals carrying APOE risk alleles or 404 displaying higher tau levels, respectively (Figure 3). Moreover, after adjusting our models by total tau we lost most CSF associations and the inflation factor was 405 406 drastically reduced to  $\lambda$ =0.86 (Figure 3). After covariation with total tau, we found 7 407 nominally significant markers in plasma and 1 nominally significant marker in CSF. Nevertheless, no proteins passed FDR correction suggesting that most mLOY 408 409 associations can be explained by the previously observed correlation between mLOY 410 and tau levels. Summary statistics for association of mLRR-Y to the CSF and plasma 411 proteins are available (Supplementary Tables 9-12).

412

#### 413 DISCUSSION

414

In the present study, we found that MCI males with high genetic risk of developing 415 mLOY have increased chances of progressing to AD over time. The autosomal loci 416 used to construct the mLOY PRS had no effect on AD progression in the female subset 417 418 of our cohort, strongly suggesting that the observed effect is produced via loss of the Y chromosome among men. Importantly, modelling mLOY through its associated genetic 419 variance allowed us to observe mLOY-induced alterations in AD pathogenesis in an 420 age-independent manner, unparalleled in previous studies. These results add to previous 421 evidence reporting mLOY as a male-specific AD pathogenic factor. 422

mLOY is the most common known form of somatic mosaicism among men [10].
Concordantly, we detected mLOY in 18.9% men aged 65–85 in our cohort. Though
classically thought of as a harmless age-related trait, recent studies have revealed that

426 mLOY increases risk for all-cause mortality and several diseases [10, 20–22]. With 427 such a high prevalence in the elderly population, interest in determining mLOY's effect 428 in age-related diseases has raised over the past decade. Previous studies reported that 429 mLOY significantly increases AD risk and progression rate [19]. A more recent 430 publication claims that transcriptomic extreme downregulation of chromosome Y 431 decreases AD resilience in men [56]. However, whether mLOY acts as an AD 432 promoting factor or is just a by-product of ageing is not yet clearly established.

Concordant with previous studies [19], we found a higher degree of mLOY mosaicism 433 (mLRR-Y) in our AD vs. control population in unadjusted Kolmogorov-Smirnoff 434 models (D=0.18124; p < 2.2e-16) and age-adjusted ANCOVA (F=68.0; p= $2.54 \cdot 10^{-16}$ ). 435 436 We then performed a case-control logistic regression in all available males in our cohort, obtaining statistically significant results (OR=2.74; p=0.01). However, even 437 though age was adjusted in our data, these results should be taken cautiously due to the 438 439 dramatic age differences between the AD and control groups (Figure 1), as age is an important risk factor for both phenotypes. Thus, aiming to reduce age confounding in 440 441 our models, we restricted analysis to men aged 65-85 years old. However, despite not completely correcting the age gap between the groups, this also reduced our sample size 442 443 (Supplementary Table 4). We found an increased degree of LOY mosaicism (mLRR-Y) in 65–85-year-old cases vs. controls (OR=2.19; p=0.09), but statistical significance was 444 not reached in the models. 445

Previous reports also found that mLOY increases the rate of AD conversion in MCI 446 males [19]. We selected individuals recruited in ACE Alzheimer Center with an MCI 447 448 diagnosis at the moment of sampling and available clinical follow ups, and fitted Cox 449 proportional-hazards models. Even though we found risk, or positive, effect directions 450 for mLOY phenotypes towards AD progression, no statistical significance was reached 451 in the models (Figure 3). However, given our small sample size (N=400), we may have lacked enough statistical power in this analysis. Remarkably, we noticed that the 452 453 quantitative mLRR-Y variable performed superiorly in the case-control and disease 454 progression models compared to mLOY calls, implying that, if effects were genuine, the mLOY-induced increase in AD risk and progression may be proportional to the mosaic 455 456 fraction of LOY cells in blood.

Due to the age-dependent nature of both mLOY and AD, controlling age confounding 457 458 was very challenging in our cohort. For this reason, we checked mLOY causality in AD by creating an instrument variable and conducted a mendelian randomization study. To 459 460 this end, we generated an age-independent and sex-independent mLOY-associated PRS, using 114 independent autosomal genetic variants (Supplementary Table 2) previously 461 associated with mLOY [14]. Of note, mloy-PRS successfully predicted mLOY events in 462 463 our data and was not associated with age or APOE genotype (Supplementary Figure 7, 464 Supplementary Table 7). A recently published work found similar effect sizes of this 465 PRS for predicting mLOY calls [57]. Therefore, analysis of mloy-PRS instead of mLOY phenotypes allowed us to overcome the main limitations of the study (age 466 467 differences and sample size) by providing an age-independent mLOY instrument, and allowing us to increase the effective sample size in two ways: (a) removing the need to 468 469 restrict analysis to samples with available age at DNA sampling information and (b) allowing us to introduce all MCI individuals with subsequent clinical records in disease 470 471 progression models instead of only those with an MCI diagnose at the closest clinical 472 evaluation to DNA sampling.

473

474 Importantly, we found a male-specific, statistically significant (HR=1.23; p=0.01) association between mloy-PRS and MCI phenoconversion to AD. Case-control models 475 also reported positive, or risk, effects of mloy-PRS in AD in the male subset (OR=1.07; 476 477 p=0.12), but no statistical significance was reached in the models, even though our sample size was considerably larger in the case-control dataset ( $N_{males}=2$  471) than in 478 479 the longitudinal, prospective MCI dataset ( $N_{males}$ =682). These results suggest that 480 mLOY could be more involved in the MCI, early clinical stages of AD etiopathogenesis 481 than in the preclinical stages of the disease, namely AD risk. However, because the PRS only explains a fraction of the variance that causes mLOY, a higher sample size may be 482 needed to reach enough statistical power to obtain more robust associations in the case-483 control models. Importantly, mloy-PRS effects were neutral in the female groups (Table 484 485 3), implying that the observed effect of mloy-PRS on AD is unlikely to be driven by the same mechanisms that confer mLOY risk (increased genomic instability and 486 impairment of DNA reparation mechanisms) [14]. Instead, the observed effects were 487 488 male-specific and therefore more likely produced via loss of the Y chromosome 489 exclusively in men.

490

One of the most commonly proposed mechanisms to explain blood cell LOY 491 492 pathogenesis is the impairment of immune functions [10, 14, 19]. Interestingly, 493 deregulation of the immune system is one of the hallmark features of AD [58], and 494 genome-wide association studies are revealing an increasing number of genes related to immune functions [30]. LOY has been reported to cause deregulation in the expression 495 levels of approximately 500 autosomal transcripts in leukocytes [24]. Furthermore, 496 497 levels of CD99, a cell surface protein involved in several key immune functions, such as 498 leukocyte migration through the vascular endothelium, cell adhesion and apoptosis [59, 499 60], have been found to be significantly lowered in immune cells with LOY [24, 54]. Thus, mLOY-induced alterations in the homeostasis and migration of leukocytes 500 501 through the brain-blood barrier could explain the observed associations. Further studies 502 are necessary to corroborate our findings and to identify the specific mechanisms within 503 mLOY modifying AD etiopathogenesis. Of note, functional restauration of the lost Ychromosome loci promoting aberrant clonal expansion or transcriptomic deregulation of 504 505 LOY leukocytes could be an attractive therapeutic strategy for combating AD 506 progression.

507

508 One strength of our study is that we modelled LOY through an age-independent PRS 509 instead of just analyzing the age-dependent mLOY phenotype and adjusting our data by 510 age. In our opinion, this allowed a clearer and more robust approach for inferring 511 causality between mLOY and AD. We also obtained an independent validation of our findings through AD-related biomarkers, with mLOY phenotypes associated with 512 513 higher levels of total tau and p-tau in the CSF and displaying the proteomic 514 neurodegenerative biochemical signature observed with other AD-related factors (Figure 3). Higher tau levels are associated with faster rates of cognitive decline [61], 515 supporting the hypothesis that mLOY modulates disease progression. This work, 516 however, also faced several limitations: a) the lack of age at sampling information for 517 most controls and b) the control population being significantly younger than the AD 518 519 population. Both of these limitations ultimately decreased our statistical power to find more robust mLOY-AD associations in the case-control models. 520

521

In summary, the present study did not find such strong associations between the blood
mLOY phenotype and AD as those reported previously [19]. Due to the demographic
features of the GR@ACE/DEGESCO cohort, with older AD patients and younger

population-based controls, adjusting our data by age was challenging. Consequently, we 525 526 modelled the genetic variance associated with mLOY risk, generating a PRS that was associated with MCI conversion to AD in a male-specific manner. This approach 527 528 allowed us to efficiently control the effect of ageing and to evaluate the potential causality of the mLOY phenotype. Furthermore, lack of association of mloy-PRS and 529 530 AD in women suggests that the observed effect is produced via the inherent loss of the 531 Y chromosome and that mLOY could be a male-specific AD risk factor. Larger studies 532 may benefit from modelling mLOY using Mendelian randomization, as case and control 533 populations do not always represent the same age groups in AD cohorts, and date of DNA sampling of the subjects may not be available. 534

535

#### 536 <u>AKNOWLEDGEMENTS</u>

537 We would like to thank patients and controls who participated in this project. The 538 present work has been performed as part of the doctoral thesis of P.G. at the University 539 of Barcelona (Barcelona, Spain). P.G. is supported by CIBERNED employment plan CNV-304-PRF-866. CIBERNED is integrated into ISCIII (Instituto de Salud Carlos 540 III). I. de Rojas is supported by a national grant from the Instituto de Salud Carlos III 541 FI20/00215. A. Cano acknowledges the support of the Spanish Ministry of Science, 542 543 Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I). 544 M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, 545 PI17/01474, PI19/01240 and PI19/01301. The Genome Research @ Fundacio ACE 546 project (GR@ACE) is supported by Grifols SA, Fundación bancaria La Caixa, Fundació ACE, and CIBERNED. Acción Estratégica en Salud is integrated into the 547 548 Spanish National  $R \square + \square D \square + \square I$  Plan and funded by ISCIII (Instituto de Salud Carlos III)-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo 549 550 Regional (FEDER—Una manera de hacer Europa). Some control samples and data from patients included in this study were provided in part by the National DNA Bank Carlos 551 III (www.bancoadn.org, University of Salamanca, Spain) and Hospital Universitario 552 553 Virgen de Valme (Sevilla, Spain); they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. 554 Genotyping of the ACE MCI-EADB samples was performed in the context of EADB 555 (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW 556 project number 733051061). This work was supported by a grant (European Alzheimer 557

558 DNA BioBank, EADB) from the EU Joint Program—Neurodegenerative Disease

559 Research (JPND).

560

561

# 562 <u>REFERENCES</u>

- 563
- Alzheimer's Association. 2021 Alzheimer's disease facts and figures. *Alzheimer's Dement*. 2021; 17:327–406.
- Wingo TS, Lah JJ, Levey AI, Cutler DJ. Autosomal recessive causes likely in
  early-onset Alzheimer disease. *Arch Neurol.* 2012; 69:59–64.
- Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al.
   Role of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry*. 2006; 63:168–174.
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J,
   Salvesen GS, et al. Apolipoprotein E: High-avidity binding to β-amyloid and
   increased frequency of type 4 allele in late-onset familial Alzheimer disease.
   *Proc Natl Acad Sci USA*. 1993; 90:1977–1981.
- 575 5. Herrup K. Reimagining Alzheimer's disease An age-based hypothesis. J
  576 Neurosci. 2010; 30:16755–16762.
- 577 6. Lin KA, Choudhury KR, Rathakrishnan BG, Marks DM, Petrella JR,
- Doraiswamy PM. Marked gender differences in progression of mild cognitive
  impairment over 8 years. *Alzheimer's Dement Transl Res Clin Interv.* 2015;
  1:103–110.
- 7. Holland D, Desikan RS, Dale AM, McEvoy LK. Higher rates of decline for
  women and apolipoprotein e ε4 carriers. *Am J Neuroradiol.* 2013; 34:2287–2293.
- Snyder HM, Asthana S, Bain L, Brinton R, Craft S, Dubal DB, et al. Sex biology
   contributions to vulnerability to Alzheimer's disease: A think tank convened by
   the Women's Alzheimer's Research Initiative. *Alzheimer's Dement*. 2016;
- 586 12:1186–1196.

587 588 589	9.	Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Dimech AS, Chadha AS, et al. Sex differences in Alzheimer disease — The gateway to precision medicine. <i>Nat Rev Neurol.</i> 2018; 14:457–469.
590 591 592	10.	Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, et al. Mosaic loss of chromosome y in peripheral blood is associated with shorter survival and higher risk of cancer. <i>Nat Genet.</i> 2014; 46:624–628.
593 594 595	11.	Jacobs PA, Brunton M, Brown WMC, Doll R, Goldstein H. Change of human chromosome count distributions with age: Evidence for a sex difference. <i>Nature</i> . 1963; 197:1080–1081.
596 597	12.	Jacobs PA, Court Brown WM, Doll R. Distribution of human chromosome counts in relation to age. <i>Nature</i> . 1961; 191:1178–1180.
598 599	13.	Guo X, Dai X, Zhou T, Wang H, Ni J, Xue J, et al. Mosaic loss of human Y chromosome: what, how and why. <i>Hum Genet</i> . 2020; 139:421–446
600 601 602	14.	Thompson DJ, Genovese G, Halvardson J, Ulirsch JC, Wright DJ, Terao C, et al. Genetic predisposition to mosaic Y chromosome loss in blood. <i>Nature</i> . 2019 575: 652–657.
603 604 605	15.	United Kingdom Cancer Cytogenetics Group. Loss of the Y chromosome from normal and neoplastic bone marrows. <i>Genes, Chromosom Cancer</i> . 1992; 5:83– 88.
606 607 608	16.	Wiktor A, Rybicki BA, Piao ZS, Shurafa M, Barthel B, Maeda K, et al. Clinical significance of Y chromosome loss in hematologic disease. <i>Genes Chromosom Cancer</i> . 2000; 27:11–16.
609 610	17.	Stone JF, Sandberg AA. Sex chromosome aneuploidy and aging. <i>Mutat Res DNAging</i> . 1995; 338:107–113
611 612 613 614	18.	Wong AK, Fang B, Zhang L, Guo X, Lee S, Schreck R. Loss of the Y chromosome: An age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome? <i>Arch Pathol Lab Med.</i> 2008 132:1329– 1332
615 616	19.	Dumanski JP, Lambert JC, Rasi C, Giedraitis V, Davies H, Grenier-Boley B, et al. Mosaic Loss of Chromosome y in Blood Is Associated with Alzheimer

617 Disease. Am J Hum Genet. 2016; 98:1208–1219.

- Noveski P, Madjunkova S, Stefanovska ES, Geshkovska NM, Kuzmanovska M,
  Dimovski A, et al. Loss of Y chromosome in peripheral blood of colorectal and
  prostate cancer patients. *PLoS One*. 2016; 11:e0146264 .
- 421 21. Haitjema S, Kofink D, Van Setten J, Van Der Laan SW, Schoneveld AH, Eales J,
  422 et al. Loss of y Chromosome in Blood Is Associated with Major Cardiovascular
  423 Events during Follow-Up in Men after Carotid Endarterectomy. *Circ Cardiovasc*424 *Genet.* 2017; 10:e001544
- Loftfield E, Zhou W, Graubard BI, Yeager M, Chanock SJ, Freedman ND, et al.
  Predictors of mosaic chromosome Y loss and associations with mortality in the
  UK Biobank. *Sci Rep.* 2018; 8:12316
- Forsberg LA. Loss of chromosome Y (LOY) in blood cells is associated with
  increased risk for disease and mortality in aging men. *Hum Genet*. 2017; 136(5):
  657–663.
- Dumanski JP, Halvardson J, Davies H, Rychlicka-Buniowska E, Mattisson J,
  Moghadam BT, et al. Immune cells lacking Y chromosome show dysregulation
  of autosomal gene expression. *Cell Mol Life Sci.* 2021; 78:4019–4033.
- Guo X. Loss of Y chromosome at the interface between aging and Alzheimer's
  disease. *Cell Mol Life Sci.* 2021; 78:7081–7084.
- Moreno-Grau S, de Rojas I, Hernández I, Quintela I, Montrreal L, Alegret M, et
  al. Genome-wide association analysis of dementia and its clinical
  endophenotypes reveal novel loci associated with Alzheimer's disease and three
- causality networks: The GR@ACE project. *Alzheimer's Dement*. 2019; 15:1333–
  1347.
- de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, et
  al. Common variants in Alzheimer's disease and risk stratification by polygenic
  risk scores. *Nat Commun.* 2021; 12:3417.
- Espinosa A, Alegret M, Valero S, Vinyes-Junqué G, Hernández I, Mauleón A, et
  al. A longitudinal follow-up of 550 mild cognitive impairment patients: Evidence
  for large conversion to dementia rates and detection of major risk factors

647 involved. J Alzheimer's Dis. 2013; 34:769–780.

648 649 650 651	29.	Lacour A, Espinosa A, Louwersheimer E, Heilmann S, Hernández I, Wolfsgruber S, et al. Genome-wide significant risk factors for Alzheimer's disease: Role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. <i>Mol Psychiatry</i> . 2017; 22:153–160.
652 653 654	30.	Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nat Genet.</i> 2022; 54:412–436.
655 656 657	31.	Boada M, Tárraga L, Hernández I, Valero S, Alegret M, Ruiz A, et al. Design of a comprehensive Alzheimer's disease clinic and research center in Spain to meet critical patient and family needs. <i>Alzheimer's Dement</i> . 2014: 10:409-415.
658 659 660 661	32.	McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of alzheimer's disease: Report of the NINCDS-ADRDA work group* under the auspices of department of health and human services task force on alzheimer's disease. <i>Neurology</i> . 1984; 34:939–944.
662 663 664 665 666	33.	McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's Dement.</i> 2011; 7:263– 269
667 668 669	34.	Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: Diagnostic criteria for research studies: Report of the ninds-airen international workshop. <i>Neurology</i> . 1993; 43:250–260.
670 671 672	35.	Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. <i>Neurology</i> . 1998; 51:1546–1554.
673 674 675	36.	Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. <i>Brain.</i> 2011; 134:2456–2477.
676	37.	McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al.

677 678		Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. <i>Neurology</i> . 2005; 65:1863–1872.
679 680 681	38.	Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. <i>Arch Neurol.</i> 1999; 56:303–308.
682 683	39.	Petersen RC. Mild cognitive impairment as a diagnostic entity. <i>J. Intern. Med.</i> 2004; 256:183–194.
684 685 686	40.	Diskin SJ, Li M, Hou C, Yang S, Glessner J, Hakonarson H, et al. Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. <i>Nucleic Acids Res.</i> 2008; 36:e126.
687 688 689 690	41.	Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SFA, et al. PennCNV: An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. <i>Genome Res.</i> 2007; 17:1665–1674.
691 692 693	42.	Wang K, Chen Z, Tadesse MG, Glessner J, Grant SFA, Hakonarson H, et al. Modeling genetic inheritance of copy number variations. <i>Nucleic Acids Res.</i> 2008. 21:e138.
694 695 696	43.	Kendall KM, Rees E, Escott-Price V, Einon M, Thomas R, Hewitt J, et al. Cognitive Performance Among Carriers of Pathogenic Copy Number Variants: Analysis of 152,000 UK Biobank Subjects. <i>Biol Psychiatry</i> . 2017; 82:103–110.
697 698 699	44.	González JR, López-Sánchez M, Cáceres A, Puig P, Esko T, Pérez-Jurado LA. MADloy: robust detection of mosaic loss of chromosome Y from genotype- array-intensity data. <i>BMC Bioinformatics</i> . 2020; 21:533.
700 701 702	45.	Rodríguez-Santiago B, Malats N, Rothman N, Armengol L, Garcia-Closas M, Kogevinas M, et al. Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. <i>Am J Hum Genet</i> . 2010; 87:129–138.
703 704 705	46.	Gogarten SM, Sofer T, Chen H, Yu C, Brody JA, Thornton TA, et al. Genetic association testing using the GENESIS R/Bioconductor package. <i>Bioinformatics</i> . 2019; 35:5346–5348.
706	47.	Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, Sanchez-Ruiz D, Abdelnour

707 708 709 710		C, Valero S, et al. FACEHBI: A Prospective Study of Risk Factors, Biomarkers and Cognition in a Cohort of Individuals with Subjective Cognitive Decline. Study Rationale and Research Protocols. <i>J Prev Alzheimer's Dis.</i> 2017; 4:100– 108.
711 712 713	48.	Pesini P, Pérez-Grijalba V, Monleón I, Boada M, Tárraga L, Martínez-Lage P, et al. Reliable measurements of the $\beta$ -amyloid pool in blood could help in the early diagnosis of AD. <i>Int J Alzheimers Dis.</i> 2012. 2012:604141.
714 715 716 717	49.	Adami PVM, Orellana A, García P, Kleineidam L, Alarcón-Martín E, Montrreal L, et al. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type. <i>Brain.</i> 2022. e-pub ahead of print 28 January 2022; doi: 10.1093/brain/awac024.
718 719 720	50.	R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R- project.org/.
721 722	51.	Arthur Allignol, Aurelien Latouche (2022). CRAN Task View: Survival Analysis. Version 2022-03-03. URL https://CRAN.R-project.org/view=Survival.
723 724	52.	Pierre R V., Hoagland HC. Age associated aneuploidy: Loss of Y chromosome from human bone marrow cells with aging. <i>Cancer</i> . 1972; 30:889–894.
725 726	53.	Viechtbauer W. Conducting Meta-analysis in R with the metafor package. <i>J Stat Softw.</i> 2010; 16:1–48.
727 728 729	54.	Mattisson J, Danielsson M, Hammond M, Davies H, Gallant CJ, Nordlund J, et al. Leukocytes with chromosome Y loss have reduced abundance of the cell surface immunoprotein CD99. <i>Sci Rep.</i> 2021; 11:15160.
730 731 732	55.	Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. <i>Alzheimer's</i> <i>Dement Transl Res Clin Interv.</i> 2018; 4:575–590.
733 734 735	56.	Caceres A, Jene A, Esko T, Perez-Jurado LA, Gonzalez JR. Extreme downregulation of chromosome Y and Alzheimer's disease in men. <i>Neurobiol</i> <i>Aging</i> . 2020; 90: 150.e1–150.e4.
736	57.	Riaz M, Mattisson J, Polekhina G, Bakshi A, Halvardson J, Danielsson M, et al.

737 738		A polygenic risk score predicts mosaic loss of chromosome Y in circulating blood cells. <i>Cell Biosci.</i> 2021; 11:205.
739 740 741	58.	Bettcher BM, Tansey MG, Dorothée G, Heneka MT. Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus. <i>Nat Rev Neurol.</i> 2021; 17:689–701.
742 743 744	59.	Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. <i>Nat Immunol.</i> 2002 3:143–150.
745 746	60.	Vestweber D. How leukocytes cross the vascular endothelium. <i>Nat Rev Immunol</i> . 2015; 15:692–704.
747 748 749	61.	Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. <i>Int J</i> <i>Geriatr Psychiatry</i> . 2010; 25:403–410.
750		
751		
752		
753		
754		
755		
756		
757		
758		
759		
760		
761		

765	Table 1. Logistic regression results using mLRR-Y and mLOY calls as predictors for AD status. 3 experimental setups were defined: a) all men with
766	available age at DNA sampling, b) 65–85-year-old men, and c) a stratification of 65–85-year-old men in age groups (65–70, 70–75, 75–80, & 80–85 years
767	old). Models were adjusted by age at blood sampling, APOE genotype, and PCs. In the age-stratified models, only the effect of mLRR-Y or mLOY are
768	displayed.

		All available males					65-85 year-old males				Stratified 65-85 year-old males						
		OR	SE	Р	CI2.5	CI97.5	OR	SE	Р	CI2.5	CI97.5	Age group	OR	SE	Р	CI2.5	CI97.5
	mLRR-Y	2.74	0.4	1.13·10 <sup>-2</sup>	1.29	6.16	2.19	0.47	9.28·10 <sup>-2</sup>	0.18	1.1	65-70	1.47	1.43	0.79	0.07	21.96
÷	Age	1.16	0.01	2.74 <b>·</b> 10 <sup>-104</sup>	<sup>₄</sup> 1.15	1.18	1.27	0.01	6.61·10 <sup>-70</sup>	1.24	1.31	70-75	1.74	0.77	0.48	0.39	8.18
mLRR	APOE	2.52	0.08	1.61·10 <sup>-32</sup>	2.17	2.94	2.86	0.10	5.40·10 <sup>-28</sup>	2.38	3.46	75-80	2.37	0.77	0.27	0.57	12.16
	PC1	2.01·10 <sup>3</sup>	2.6	3.39·10 <sup>-3</sup>	12.48	3.29·10 <sup>5</sup>	0.01	3.33	0.11	0.00	3.48	80-85	44.44	2.51	0.13	0.99	2.63·10 <sup>4</sup>
	PC2	0.02	2.58	0.15	0.00	3.8	0.00	3.45	0.12	0.00	4.00	META	2.20	0.50	0.115	0.83	5.88
	mLOY	1.14	0.14	0.35	0.87	1.49	1.04	0.16	0.81	0.76	1.43	65-70	0.55	0.45	0.19	0.22	1.30
mLOY calls	Age	1.16	0.01	1.11·10 <sup>-100</sup>	<sup>3</sup> 1.15	1.18	1.28	0.01	1.73·10 <sup>-71</sup>	1.24	1.31	70-75	1.17	0.3	0.6	0.65	2.11
	APOE	2.52	0.08	2.17·10 <sup>-32</sup>	2.17	2.94	2.86	0.10	6.93·10 <sup>-28</sup>	2.37	3.46	75-80	1.00	0.25	0.99	0.62	1.66
	PC1	2.29·10 <sup>3</sup>	2.59	2.78·10 <sup>-3</sup>	14.5	3.69·10 <sup>-5</sup>	0.00	3.32	0.10	0.00	2.96	80-85	3.70	0.77	0.09	1.00	24.08
	PC2	0.02	2.58	0.14	0.00	3.44	0.00	3.44	0.11	0.00	3.34	META	1.03	0.17	0.86	0.74	1.45

#### Table 2. Cox proportional-hazards model results for conversion of MCI males to all-cause-dementia or AD-dementia. Models were

adjusted by age at sampling and APOE genotype. 

### 

	Conversi	ion to all-caus	e-dementia		Conversion to AD-dementia				
	HR	SE	P-value	CI95 %	HR	SE	P-value	CI95 %	
Association	results for n	nLRR-Y (contin	uous mLOY varia	ble)					
mLRR-Y	1.93	0.40	0.10	0.87-4.27	2.05	0.55	0.19	0.70-5.97	
Age	1.10	0.01	3.62·10 <sup>-15</sup>	1.07-1.12	1.13	0.02	2.38·10 <sup>-12</sup>	1.09-1.16	
APOE	1.29	0.13	4.10·10 <sup>-02</sup>	1.01-1.66	1.56	0.17	8.89·10 <sup>-3</sup>	1.12-2.17	
Association	results for n	nLOY calls							
mLOY	1.17	0.19	0.40	0.81-1.70	1.38	0.25	0.20	0.85-2.24	
Age	1.10	0.01	1.33·10 <sup>-15</sup>	1.07-1.13	1.13	0.02	1.62·10 <sup>-12</sup>	1.09-1.17	
APOE	1.28	0.13	5.09·10 <sup>-2</sup>	1.00-1.63	1.54	0.17	1.05E·10 <sup>-2</sup>	1.11-2.13	

775	Table 3. Association results for mLOY PRS. (a) Results of logistic regressions for case-control AD. Only individuals aged 65–85 were included in the
776	models. Models were adjusted by APOE, age, and principal components. (b) Results of joint analysis of prospective MCIs in the GR@ACE-DEGESCO and
777	EADB-DEGESCO cohorts using Cox proportional-hazards models for progression from MCI to all-cause dementia or AD. Models were adjusted by APOE,
778	age, and cohort ascertainment.

~	1 0000400	roarooion	rooutto	
-	1 1 1 1 1 1 1 1 1 1		1 DOLLING	
с.			<i>i</i> couno.	

	OR	SE	Z	P-value	2.5 % CI	97.5 % CI
CASE-CONTROL, ALL	1.03	0.03	1.09	0.28	0.98	1.09
CASE-CONTROL, MALES	1.07	0.05	1.55	0.12	0.98	1.18
CASE-CONTROL, FEMALES	1.00	0.03	0.10	0.93	0.90	1.10

779

# b. Cox model results:

	HR	SE	Z	P-value	2.5 % Cl	97.5 % Cl
ALL, MCI to dementia	1.04	0.04	0.97	0.33	0.96	1.12
ALL, MCI to AD	1.07	0.05	1.45	0.15	0.98	1.16
MALES, MCI to dementia	1.11	0.06	1.77	<b>7.68</b> ·10 <sup>-2</sup>	0.99	1.26
MALES, MCI to AD	1.23	0.08	2.53	1.14·10 <sup>-2</sup>	1.05	1.43
FEMALES, MCI to dementia	0.99	0.05	-0.23	0.81	0.90	1.08
FEMALES, MCI to AD	0.99	0.06	-0.19	0.85	0.89	1.11

**Figure 1. mLRR-y variation with age in the GR@ACE-DEGESCO cohort. a.** Age and mLRR-Y distribution in the case and control groups. The dots represent mLRR-Y values for individual samples and the histogram represents the age distribution across the case and control groups **b**. Proportion of individuals with mLOY in the different age groups based on age at blood sampling. **c–d** mLRR-Y distribution for the different age groups based on age at blood sampling in control and AD individuals, respectively.





**Figure 2.** Association of mLOY phenotypes with risk of conversion to dementia and AD-dementia over time for MCI males in the GR@ACE-DEGESCO cohort. Kaplan-Meier plots showing survival time in years for conversion to dementia (a) or AD (b) for individuals with LOY (blue) or without LOY (red) for prospective MCI males in the GR@ACE-DEGESCO cohort.



Figure 3. mLRR-Y associations with CSF protein levels. a-c. Forest plots showing the effect size obtained in linear regression models for mLRR-Y on Abeta-42 (a), phospho-Tau (b), and total Tau (c) in males with MCI or dementia, along with meta-analysis results. Volcano plots showing d–q. association of CSF proteins in the **Olink Inflammation and Neurology** panels with mLRR-Y (d), mLRR-Y adjusted by total Tau (e), APOE genotype (f), and total Tau (g). h**k**. QQ plots obtained in the models for mLRR-Y (h), mLRR-Y adjusted by total Tau (i), APOE genotype (j), and total Tau (k). Models were adjusted by age, the time window between CSF and DNA sampling, and APOE genotype.